Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome.

Patel RK, Lea NC, Heneghan MA, Westwood NB, Milojkovic D, Thanigaikumar M, Yallop D, Arya R, Pagliuca A, Gäken J, Wendon J, Heaton ND, Mufti GJ.

Gastroenterology. 2006 Jun;130(7):2031-8.

PMID:
16762626
2.

Prevalence of JAK29V617F) mutation in intra-abdominal venous thrombosis.

Deepak A, Punamiya S, Patel N, Parekh S, Mehta S, Shah N.

Trop Gastroenterol. 2011 Oct-Dec;32(4):279-84.

PMID:
22696908
3.

The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.

Michiels JJ, De Raeve H, Berneman Z, Van Bockstaele D, Hebeda K, Lam K, Schroyens W.

Semin Thromb Hemost. 2006 Jun;32(4 Pt 2):307-40. Review.

PMID:
16810609
5.

Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).

Michiels JJ, Bernema Z, Van Bockstaele D, De Raeve H, Schroyens W.

Pathol Biol (Paris). 2007 Mar;55(2):92-104. Epub 2006 Aug 21. Review.

PMID:
16919893
6.

Meta-analysis: the significance of screening for JAK2V617F mutation in Budd-Chiari syndrome and portal venous system thrombosis.

Qi X, Yang Z, Bai M, Shi X, Han G, Fan D.

Aliment Pharmacol Ther. 2011 May;33(10):1087-103. doi: 10.1111/j.1365-2036.2011.04627.x. Epub 2011 Mar 13.

7.

JAK2 V617F mutation and 46/1 haplotype in Chinese Budd-Chiari syndrome patients.

Wang H, Sun G, Zhang P, Zhang J, Gui E, Zu M, Jia E, Xu H, Xu L, Zhang J, Lu Z.

J Gastroenterol Hepatol. 2014 Jan;29(1):208-14. doi: 10.1111/jgh.12379.

PMID:
23980667
8.

JAK2 mutations across a spectrum of venous thrombosis cases.

Shetty S, Kulkarni B, Pai N, Mukundan P, Kasatkar P, Ghosh K.

Am J Clin Pathol. 2010 Jul;134(1):82-5. doi: 10.1309/AJCP7VO4HAIZYATP.

PMID:
20551270
9.

JAK2 in myeloproliferative disorders is not just another kinase.

Tefferi A, Gilliland DG.

Cell Cycle. 2005 Aug;4(8):1053-6. Epub 2005 Aug 26.

PMID:
15970705
11.

The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases.

Kiladjian JJ, Cervantes F, Leebeek FW, Marzac C, Cassinat B, Chevret S, Cazals-Hatem D, Plessier A, Garcia-Pagan JC, Darwish Murad S, Raffa S, Janssen HL, Gardin C, Cereja S, Tonetti C, Giraudier S, Condat B, Casadevall N, Fenaux P, Valla DC.

Blood. 2008 May 15;111(10):4922-9. doi: 10.1182/blood-2007-11-125328. Epub 2008 Feb 4.

12.

Hypereosinophilia, JAK2V617F, and Budd-Chiari syndrome: who is responsible for what?

Mishchenko E, Tadmor T, Schiff E, Attias D, Polliack A.

Am J Hematol. 2011 Feb;86(2):223-4. doi: 10.1002/ajh.21926.

13.

JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.

Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, Villeval JL.

Blood. 2006 Sep 1;108(5):1652-60. Epub 2006 May 2.

14.

Case 15-2006: the Budd-Chiari syndrome and V617F mutation in JAK2.

Spivak JL, Moliterno AR, Silver RT.

N Engl J Med. 2006 Aug 17;355(7):737; author reply 738. No abstract available.

15.

Detection of the activating JAK2 V617F mutation in paraffin-embedded trephine bone marrow biopsies of patients with chronic myeloproliferative diseases.

Horn T, Kremer M, Dechow T, Pfeifer WM, Geist B, Perker M, Duyster J, Quintanilla-Martinez L, Fend F.

J Mol Diagn. 2006 Jul;8(3):299-304.

16.

Occurrence of the JAK2 V617F mutation in the Budd-Chiari syndrome.

Colaizzo D, Amitrano L, Tiscia GL, Iannaccone L, Gallone A, Grandone E, Guardascione MA, Margaglione M.

Blood Coagul Fibrinolysis. 2008 Jul;19(5):459-62. doi: 10.1097/MBC.0b013e3283049662.

PMID:
18600100
17.

The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera.

Tefferi A, Lasho TL, Schwager SM, Strand JS, Elliott M, Mesa R, Li CY, Wadleigh M, Lee SJ, Gilliland DG.

Cancer. 2006 Feb 1;106(3):631-5.

18.

The JAK2(V617F) tyrosine kinase mutation identifies clinically latent myeloproliferative disorders in patients presenting with hepatic or portal vein thrombosis.

Goulding C, Uttenthal B, Foroni L, Duke V, Traore A, Kottaridis P, Hoffbrand AV, Patch D, McNamara C.

Int J Lab Hematol. 2008 Oct;30(5):415-9. doi: 10.1111/j.1751-553X.2007.00973.x.

PMID:
19046316
19.

JAK2V617F and prothrombin G20210A gene mutations in a patient with Budd-Chiari syndrome and essential thrombocythemia.

Musallam KM, Aoun EG, Mahfouz RA, Khalife M, Taher AT.

Clin Appl Thromb Hemost. 2010 Aug;16(4):472-4. doi: 10.1177/1076029609332110. Epub 2009 Feb 16.

PMID:
19223280
20.

[Detection and clinical significance of JAK2 mutation in 412 patients with chronic myeloproliferative neoplasms].

Chao HY, Fan Z, Zhang R, Shen YM, Chen W, Fei HR, Zhu ZL, Feng YF, Chen ZX, Xue YQ.

Zhonghua Zhong Liu Za Zhi. 2009 Jul;31(7):510-4. Chinese.

PMID:
19950698

Supplemental Content

Support Center